Dryden-Peterson Scott, Lockman Shahin, Zash Rebecca, Lei Quonhong, Chen Jennifer Y, Souda Sajini, Petlo Chipo, Dintwa Eldah, Lebelonyane Refeletswe, Mmalane Mompati, Shapiro Roger L
*Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; †Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; ‡Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA; §Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA; ‖Department of Biostatistics, Harvard School of Public Health, Boston, MA; ¶Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA; #Department of Pathology, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana; and **Department of HIV/AIDS Prevention and Care, Ministry of Health, Gaborone, Botswana.
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):245-9. doi: 10.1097/QAI.0000000000000482.
: Botswana was one of the first African countries to transition from WHO Option A to Option B for prevention of mother-to-child HIV transmission (MTCT). We evaluated the impact of this transition on projected MTCT risk through review of 10,681 obstetric records of HIV-infected women delivering at 6 maternity wards. Compared with Option A, women receiving antenatal care under Option B were more likely to receive combination antiretroviral therapy (ART), adjusted odds ratio (aOR): 2.59 (95% confidence interval: 2.25 to 2.98), but they were also more likely to receive no antenatal antiretrovirals, aOR: 2.10 (95% confidence interval: 1.74 to 2.53). Consequently, initial implementation of Option B was associated with increased projected MTCT at 6 months of age, 3.79% under Option A and 4.69% under Option B (P < 0.001). Successful implementation of Option B or B+ may require that ART can be initiated within antenatal clinics, and novel strategies to remove barriers to rapid ART initiation.
博茨瓦纳是首批从世界卫生组织预防母婴传播艾滋病毒(MTCT)的A方案过渡到B方案的非洲国家之一。我们通过回顾在6个产科病房分娩的10681名感染艾滋病毒妇女的产科记录,评估了这一过渡对预计MTCT风险的影响。与A方案相比,接受B方案产前护理的妇女更有可能接受抗逆转录病毒联合疗法(ART),调整后的优势比(aOR):2.59(95%置信区间:2.25至2.98),但她们也更有可能未接受任何产前抗逆转录病毒药物,aOR:2.10(95%置信区间:1.74至2.53)。因此,B方案的初步实施与6个月大时预计的MTCT增加有关,A方案下为3.79%,B方案下为4.69%(P<0.001)。成功实施B方案或B+方案可能需要在产前诊所内启动抗逆转录病毒治疗,以及采取新策略消除快速启动抗逆转录病毒治疗的障碍。